A new stemcell therapy shows promise in treating hair loss, but skepticism remains about its availability. Users humorously discuss the effectiveness of treatments on mice compared to humans.
Pelage is developing a topical hair follicle stemcell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.
Microneedling stimulates hair growth through stemcell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.
The conversation is about hair transplants in America, specifically the availability of DHI. The user is currently using finasteride and plans to use microneedling, oral castor oil, and eventually undergo FUE or DHI.
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stemcells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stemcells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.
Using a combination of micro-needling and exosome injections as a potential treatment for male pattern baldness, which could result in 50% or more regrowth.
Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
The user is pleased with their hair growth progress after 5 months of using Minoxidil, Finasteride, and RU58841, and is curious if the baby hairs at the temple will fully connect with the rest of the hair. It's uncertain if the connection will happen yet.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A drug that regrows body parts, but not hair, sparking debate on hair loss treatments. Discussions include the use of finasteride, dutasteride, and the potential for new methods to restore hair.
Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.
The user wants to donate plasma to save for a hair transplant but can't take finasteride or dutasteride due to plasma center restrictions. They are considering using minoxidil and biotin instead and are seeking advice on alternative treatments.
Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
Exosome stemcell treatment for hair loss, which is expensive and reportedly effective, but its popularity has declined. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
The user shared their positive experience with a hair transplant in South Korea, highlighting thorough consultations, consistent medical team involvement, and reasonable pricing. They noted good growth and natural-looking results after several months, with stemcell PRP treatment included to support graft survival.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.